Key features and details
- Sensitivity: 30 ng/ml
- Range: 100 ng/ml - 3000 ng/ml
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
Product nameAvelumab ELISA Kit
See all Avelumab kits
Intra-assay Sample n Mean SD CV% Overall < 15% Inter-assay Sample n Mean SD CV% Overall < 15%
Sample typeSerum, Plasma
Assay typeSandwich (quantitative)
Range100 ng/ml - 3000 ng/ml
Sample specific recovery Sample type Average % Range Serum 85% - 115%
Assay durationMultiple steps standard assay
Species reactivityReacts with: Human
Note: Avelumab ELISA kit ab237669 is intended for Research Use Only, not for use in diagnostic procedures.
This kit is a sandwich based ELISA kit. The color developed is proportional to the amount of Avelumab in the sample or standard. Results of samples can be determined directly using the standard curve.
Storage instructionsStore at +4°C. Please refer to protocols.
Components 96 tests Assay Buffer 2 x 50ml Avelumab Standard S1 1 x 0.1ml Avelumab Standard S2 1 x 0.1ml Avelumab Standard S3 1 x 0.1ml Avelumab Standard S4 1 x 0.1ml Avelumab Standard S5 1 x 0.1ml Avelumab Standard S6 1 x 0.1ml Avelumab Standard S7 1 x 0.1ml HRP-conjugate Probe 1 x 12ml Micro ELISA Plate 1 unit Plate sealers 2 units Stop Solution 1 x 12ml TMB substrate 1 x 12ml Wash buffer (20X) 1 x 50ml
RelevanceAvelumab (Bavencio®) is a fully human anti-PD-L1 IgG1 lambda monoclonal antibody that has a molecular weight of approximately 147 kDa. Avelumab binds PD-L1 and blocks the interaction between PD-L1 and its receptors PD-1 and B7-1. By inhibiting PD-L1 interactions, avelumab is thought to enable the activation of T-cells and the adaptive immune system. By retaining anative Fc-region, avelumab is thought to engage the innate immune system and may induce antibody-dependent cell-mediated cytotoxicity. Importantly, avelumab has not shown antibody-dependent cell mediated cytotoxicity against immune cell subsets in humans.
ab237669 has been referenced in 1 publication.
- Kanemaru H et al. Single administration of avelumab induced a complete response in thyroid transcription factor 1-positive combined Merkel cell carcinoma. J Dermatol 47:1317-1321 (2020). PubMed: 32794263